CVA Family Office’s Legend Biotech LEGN Stock Holding History

CVA Family Office’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15	Closed	-$489	–	1337
2025 Q3	$489	Hold	15	–	–	﹤0.01%	1253
2025 Q2	$532	Buy	+15	New	+$486	﹤0.01%	1218

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

CVA Family Office's LEGN Position: Q4 2025 in Review

CVA Family Office sold out of Legend Biotech (LEGN) in Q4 2025, closing a stake of 15 shares — an estimated $489 sold.

CVA Family Office first reported a position in LEGN in Q2 2025 and held it in 2 quarters. The position peaked at $532 in Q2 2025. 200 funds tracked by Wall St. Rank hold LEGN as of Q4 2025.

CVA Family Office reported no remaining Legend Biotech position as of Q4 2025 after selling out during the quarter.
CVA Family Office sold 15 Legend Biotech shares in Q4 2025, an estimated $489.
CVA Family Office first reported a position in Legend Biotech in Q2 2025 and held it in 2 quarters.
CVA Family Office's Legend Biotech position peaked at $532 in Q2 2025.
200 funds tracked by Wall St. Rank held Legend Biotech as of Q4 2025.

Based on CVA Family Office's 13F filing for Q4 2025, filed 12 Jan 2026.